<DOC>
	<DOCNO>NCT00660140</DOCNO>
	<brief_summary>To determine activity gemcitabine combine carboplatin treatment patient metastatic recurrent cholangiocarcinoma gallbladder cancer .</brief_summary>
	<brief_title>Study Gemcitabine Carboplatin Treatment Metastatic Recurrent Cholangiocarcinoma/Gallbladder Cancer</brief_title>
	<detailed_description>Due good non-hematologic toxicity profile , less need pre- post chemotherapy hydration , tolerability compare cisplatin , propose combine gemcitabine carboplatin treatment patient cholangiocarcinoma gallbladder carcinoma . In lung cancer , available literature suggest carboplatin efficacious cisplatin . Several Phase I , II III study use gemcitabine carboplatin already do currently ongoing . Phase I study determine maximum tolerated dos ( MTD ) gemcitabine 800-1250 mg/m2 day 1 8 combine AUC 4-5.5 , day 1 21-day cycle . Initial Phase II study use 28-day schedule use gemcitabine day 1,8 15 carboplatin cause severe thrombocytopenia day 15 preclude day 15 treatment 50 % course . A Spanish Lung Cancer Group conduct sequential Phase II trial wherein 52 % 30 % first 33 patient lung cancer treat use 28-day schedule note Grade 4 thrombocytopenia neutropenia , respectively . Subsequently , next 56 patient treat 21-day schedule , despite high dose intensity , response rate equal ( 45-48 % ) less Grade 4 thrombocytopenia ( 21 % ) similar rate Grade 4 neutropenia ( 27 % ) . A randomized Italian Phase II study demonstrate gemcitabine give dos 1 g/m2 carboplatin AUC 5 mg/mL/min tolerable compare gemcitabine cisplatin cause less non-hematologic toxicity . Current Phase III trial lung cancer utilizes 21-day schedule gemcitabine 1000 mg/m2 day 1 8 carboplatin AUC 5.5 . Therefore , propose schedule gemcitabine 1000 mg/m2 IV 30 minute day 1 8 carboplatin dose AUC 5 day 1 21-day cycle .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Patients must biopsyproven locallyadvanced , metastatic recurrent adenocarcinoma biliary duct gallbladder . 2 . Patients must measurable disease . 3 . Patients must 18 year old . 4 . Patients must NCI CTC Performance Status 02 . 5 . Patients must life expectancy &gt; = 3 month . 6 . Patients must prior chemotherapy metastatic disease . Prior adjuvant radiation therapy chemotherapy 5FU and/or gemcitabine allow . 7 . At least 3 week elapse since surgery require general anesthesia . 8 . Patients must prior malignancy except basal squamous skin cancer , cervical carcinomainsitu . 9 . Pregnant patient eligible . Nonpregnant status determine woman childbearing potential . All patient require use effective mean contraception sexually active therapy . 10 . Initial Required Laboratory Values : 1 . Absolute neutrophil count &gt; = 1,500/mm3 , platelet count &gt; = 100,000/mm3 , hemoglobin &gt; = 9 g/dL . 2 . Serum creatinine &lt; = 2 mg/dL . 3 . Serum bilirubin &lt; = 3.0 mg/dL ( biliary stent allow ) . 4 . Serum transaminases &lt; = 5fold institutional upper limit . 11 . Patients must coexist severe medical illness , unstable angina , uncontrolled diabetes mellitus , uncontrolled arrhythmia uncontrolled infection . 12 . Patients must able sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>Gallbladder</keyword>
	<keyword>Cancer</keyword>
</DOC>